Antimicrobial susceptibility of Moraxella catarrhalis in Russia: results of the PEGAS 2010–2021 multicenter study | CMAC

Antimicrobial susceptibility of Moraxella catarrhalis in Russia: results of the PEGAS 2010–2021 multicenter study

Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):188-193

​ Ivanchik N.V., Chagaryan A.N., Mikotina A.V., Trushin I.V., Kozlov R.S., Valiullina I.R., Lazareva A.V., Morozova O.A., Zubareva N.A., Moskvitina E.N.
10.36488/cmac.2024.2.188-193
Moraxella catarrhalis sensitivity antibiotic resistance
Section
Antimicrobial Resistance
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):188-193

Objective.

To study the antimicrobial susceptibility profile of Moraxella catarrhalis isolates from different regions of Russia in 2010–2021.

Materials and Methods.

The study included 352 isolates of M. catarrhalis isolated in 11 cities of Russia (Volgograd, Irkutsk, Kazan, Kirov, Moscow, Murmansk, Perm, Seversk, Togliatti, Tomsk, and Ulan-Ude) in 2010–2021. Identification was done by MALDI-TOF mass spectrometry. Antimicrobial susceptibility testing was determined by broth microdilution method in accordance with the ISO 20776-1:2020. Interpretation of results was done in accordance with EUCAST guidelines (v.14.0).

Results.

Most of the isolates were isolated from respiratory specimens: 225 (63.9%) from sputum, 49 (13.9%) from nasal swabs, 41 (11.6%) from sinus aspirates, 17 (4.8%) from bronchoalveolar lavage, 8 (2.3%) from middle ear fluid, 6 (1.7%) from pharyngeal swabs, and 5 (1.4%) from conjunctival secretions. All tested isolates were susceptible to beta-lactams for which interpretive criteria have been established (amoxicillin-clavulanate, cefixime, ceftriaxone, cefuroxime). The susceptibility to clarithromycin and azithromycin was 99.7% and 100%, respectively. Ciprofloxacin, levofloxacin and moxifloxacin were active against 98.9%, 99.2% and 99.7% of isolates tested, respectively. Susceptibility to tetracycline was 99.7% and to trimethoprim-sulfamethoxazole was 99.4% (92% of isolates susceptible, 7.4% – susceptible at increased exposure).

Conclusions.

In the Russian Federation there is a favorable situation regarding the susceptibility of M. catarrhalis to antimicrobials. Amoxicillin-clavulanic acid, cefixime, ceftriaxone, azithromycin, clarithromycin, ciprofloxacin, levofloxacin, moxifloxacin and tetracycline retain high in vitro activity

Nataly V. Ivanchik

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Aida N. Chagaryan

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Anna V. Mikotina

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Ivan V. Trushin

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Valiullina I.R.

Republican Clinical Hospital, Kazan, Russia

Lazareva A.V.

National Medical Research Center for Children's Health, Moscow, Russia

Morozova O.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Zubareva N.A.

Perm State Medical University named after E.A. Wagner, Perm, Russia

Ekaterina N. Moskvitina

Siberian Federal Research and Clinical Center, Seversk, Russia

  • 1. Gao Y., Lee J, Widmalm G., Im W. Preferred conformations of lipooligosaccharides and oligosaccharides of Moraxella catarrhalis. Glycobiology. 2020;30:86-94. DOI: 10.1093/glycob/cwz086
  • 2. Ren D., Pichichero M.E. Vaccine targets against Moraxella catarrhalis. Expert Opin Ther Targets. 2016;20:19-33. DOI: 10.1517/14728222.2015.1081686
  • 3. de Vries S.P., Bootsma H.J., Hays J.P., Hermans P.W. Molecular aspects of Moraxella catarrhalis pathogenesis. Microbiol Mol Biol Rev. 2009;73(3):389-406. DOI: 10.1128/MMBR.00007-09
  • 4. Bosch A.A., Biesbroek G., Trzcinski K., Sanders E.A., Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013;9(1):e1003057. DOI: 10.1371/journal.ppat.1003057
  • 5. Marchisio P., Esposito S., Picca M., Baggi E., Terranova L., Orenti A., et al. Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation. Clin Microbiol Infect. 2017;23(7):486.e1486.e6. DOI: 10.1016/j.cmi.2017.01.010
  • 6. Murphy T.F., Bakaletz L.O., Smeesters P.R. Microbial interactions in the respiratory tract. Pediatr Infect Dis J. 2009;28(Suppl. 10):121-126. DOI: 10.1097/INF.0b013e3181b6d7ec
  • 7. Monasta L., Ronfani L., Marchetti F., Montico M., Vecchi Brumatti L., Bavcar A., et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012;7(4):e36226. DOI: 10.1371/journal.pone.0036226
  • 8. Ngo C.C., Massa H.M., Thornton R.B., Cripps A.W. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS One. 2016;11(3):e0150949. DOI: 10.1371/journal.pone.0150949
  • 9. Murphy T.F., Parameswaran G.I. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis. 2009;49(1):124-131. DOI: 10.1086/599375
  • 10. Wilkinson T.M.A., Aris E., Bourne S., Clarke S.C., Peeters M., Pascal T.G., et al.; AERIS Study Group. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72(10):919-927. DOI: 10.1136/thoraxjnl-2016-209023
  • 11. Leung A.K., Hon K.L., Chu W.C. Acute bacterial sinusitis in children: an updated review. Drugs Context. 2020;9:20209-3. DOI: 10.7573/dic.2020-9-3
  • 12. Gadsby N.J., Musher D.M. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev. 2022;35(4):e0001522. DOI: 10.1128/cmr.00015-22
  • 13. Stefanou J., Agelopoulou A.V., Sipsas N.V., Smilakou N., Avlami A. Moraxella catarrhalis endocarditis: case report and review of the literature. Scand J Infect Dis. 2000;32(2):217218. DOI: 10.1080/003655400750045394
  • 14. Shahani L., Tavakoli Tabasi S. Moraxella catarrhalis bacteraemia and prosthetic valve endocarditis. BMJ Case Rep. 2015;2015:bcr2014207368. DOI: 10.1136/bcr2014-207368
  • 15. Abuhammour W.M., Abdel-Haq N.M., Asmar B.I., Dajani A.S. Moraxella catarrhalis bacteremia: a 10-year experience. South Med J. 1999;92(11):1071-1074. DOI: 10.1097/00007611-199911000-00005
  • 16. Paul A.C., Varkki S., Mathews M.S., Moses P.D. Pseudogonococcal ophthalmia neonatorum. Indian Pediatr. 2000;37(12):1368-1370. PMID: 11119341.
  • 17. Rotta A.T., Asmar B.I., Ballal N., Canady A. Moraxella catarrhalis ventriculitis in a child with hydrocephalus and an external ventricular drain. Pediatr Infect Dis J. 1995;14:397-398. DOI: 10.1097/00006454199505000-00015
  • 18. Sadjadi S.A., Obedoza P., Annamarju P. Moraxella catarrhalis peritonitis. Am J Case Rep. 2012;13:19-21. DOI: 10.12659/AJCR.882358
  • 19. Verjano Sánchez F., Calvo Rey C., Nebreda Pérez V. Osteomielitis por Moraxella catarrhalis en un lactante [Moraxella catarrhalis as a cause of osteomyelitis in the infant]. An Esp Pediatr. 2002;56(2):190-191. PMID: 11827662.
  • 20. Olivieri I., Padula A., Armignacco L., Sabatella V., Mancino M. Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondarthritis. Ann Rheum Dis. 2004;63(1):105-106. DOI: 10.1136/ard.2003.006270
  • 21. Hsu S.F., Lin Y.T., Chen T.L., Siu L.K., Hsueh P.R., Huang S.T., Fung C.P. Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan. J Microbiol Immunol Infect. 2012;45(2):134-140. DOI: 10.1016/j.jmii.2011.09.004
  • 22. Shaikh S.B., Ahmed Z., Arsalan S.A., Shafiq S. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections. Infect Drug Resist. 2015;8:263-267. DOI: 10.2147/IDR.S84209
  • 23. Du Y., Zhou H., Wang F., Liang S., Cheng L., Du X., et al. Multilocus sequence typing-based analysis of Moraxella catarrhalis population structure reveals clonal spreading of drug-resistant strains isolated from childhood pneumonia. Infect Genet Evol. 2017;56:117-124. DOI: 10.1016/j.meegid.2017.11.018
  • 24. Yamada K., Arai K., Saito R. Antimicrobial susceptibility to β-lactam antibiotics and production of BRO β-lactamase in clinical isolates of Moraxella catarrhalis from a Japanese hospital. J Microbiol Immunol Infect. 2017;50(3):386389. DOI: 10.1016/j.jmii.2016.08.003
  • 25.
    1. European Committee on Antimicrobial Susceptibility testing (EUCAST). Expected resistant and susceptible phenotypes. Available at: https://www.eucast.org/expert_rules_and_expected_phenotypes/expected_phenotypes. Accessed December 2023.
  • 26. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. Diagn Microbiol Infect Dis. 2012;74(2):198-200. DOI: 10.1016/j.diagmicrobio.2012.06.007
  • 27. Gupta N., Arora S., Kundra S. Moraxella catarrhalis as a respiratory pathogen. Indian J Pathol Microbiol. 2011;54(4):769-771. DOI: 10.4103/03774929.91496
  • 28. Maraki S., Papadakis I.S. Antimicrobial resistance trends among community-acquired respiratory tract pathogens in Greece, 2009-2012. ScientificWorldJournal. 2014;2014:941564. DOI: 10.1155/2014/941564
  • 29. Iwata S., Sato Y., Toyonaga Y., Hanaki H., Sunakawa K. Genetic analysis of a pediatric clinical isolate of Moraxella catarrhalis with resistance to macrolides and quinolones. J Infect Chemother. 2015;21(4):308-311. DOI: 10.1016/j.jiac.2014.11.002
  • 30. Handbook of microbiological media. By Roland M. Atlas. 2nd ed.: CRS Press; 1997. 1946 p.
  • 31. ISO 20776-1:2020 Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases (ISO 207761:2019, including Corrected version 2019-12.)
  • 32. European Committee on Antimicrobial Susceptibility testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Ver. 13.1, 2023. Аvailable at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf. Accessed December 2023.
  • 33. Zhao C., Yang S., Zhang F., Wang Z., Zhang Y., Wang X., et al. Antimicrobial resistance trends of the most common causative pathogens associated with community-acquired respiratory infections in China: 2009-2018. Infect Drug Resist. 2022;15:5069-5083. DOI: 10.2147/IDR.S374805
  • 34. Shi W., Wen D., Chen C., Yuan L., Gao W., Tang P., et al. β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China. BMC Microbiol. 2018;18(1):77. DOI: 10.1186/s12866-018-1217-5
  • 35. Liu Y., Zhao C., Zhang F., Chen H., Chen M., Wang H. High prevalence and molecular analysis of macrolidenonsusceptible Moraxella catarrhalis isolated from nasopharynx of healthy children in China. Microb Drug Resist. 2012;18(4):417-426. DOI: 10.1089/mdr.2011.0175
  • 36. Zhao N., Ren H., Deng J., Du Y., Li Q., Zhou P., et al. Genotypic and phenotypic characteristics of Moraxella catarrhalis from patients and healthy asymptomatic participants among preschool children. Pathogens. 2022;11(9):984. DOI: 10.3390/pathogens11090984
  • 37. Zhang Y., Zhang F., Wang H., Zhao C., Wang Z., Cao B., et al. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract infections in China: results from the CARTIPS Antimicrobial Surveillance Program. J Glob Antimicrob Resist. 2016;5:36-41. DOI: 10.1016/j.jgar.2016.03.002
  • 38. Sun X., Zhang B., Xu G., Chen J., Shang Y., Lin Z., et al. In vitro activity of the novel tetracyclines, tigecycline, eravacycline, and omadacycline, against Moraxella catarrhalis. Ann Lab Med. 2021;41(3):293-301. DOI: 10.3343/alm.2021.41.3.293
Views
0 Abstract
0 PDF
0 Crossref citations
Shared